

REMARKS

Claim 2 has been amended to clarify the ambiguity caused by a recitation that a protein has a nucleotide sequence.

Claim 9 has been amended to correct the ambiguity caused by a lack of proper antecedent basis.

Claim 12 has been amended to prevent a construction of the claim as reading on the gene as it occurs in nature. The recitation of "isolated" is supported at column 6, line 55 through column 7, line 8.

Claim 13 is amended to correct the improper antecedent basis for the "gene".

Claim 17 is amended to include constructs containing less than the entire INGAP coding sequence. Portions of INGAP are disclosed as having activity at column 7, lines 66 through column 8, line 13. As stated at line 8, lines 54-56 an mRNA complementary to native mammalian INGAP transcript is produced to inhibit expression of INGAP and prevent overgrowth of beta cells.

Claims 20-21 recite a vector and host cell comprising the DNA of claim 2. This is supported at column 6, lines 10-14.

Claims 22-23 recite a cDNA molecule according to claims 1 and 12, respectively. This is supported by disclosures of cDNA sequences at column 5, line 63 and methods of obtaining such sequences at column 6, line 55 and followings.


Claim 24 specifies that the DNA molecule encodes a portion of INGAP. Portions of INGAP are disclosure as biologically active at column 7, line 65 through column 8, line 13. DNA encoding such segments are disclosed at column 6, line 55 through column 7, line 3.

It is respectfully submitted that no new mater is added in this preliminary amendment.

Respectfully submitted,

Date: November 22, 2000

By:



Sarah A. Kagan

Registration No. 32,141

Banner & Witcoff, Ltd.
1001 G Street, N.W., Eleventh Floor
Washington, D.C. 20001-4597
(202) 508-9100
SAK/ama

004709E-4597